<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24422" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Lorazepam</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ghiasi</surname>
            <given-names>Noman</given-names>
          </name>
          <aff>American Un of the Caribbean School Med</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bhansali</surname>
            <given-names>Rakesh Kumar</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Marwaha</surname>
            <given-names>Raman</given-names>
          </name>
          <aff>Case Western Reserve Un/MetroHealth MC</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Noman Ghiasi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rakesh Kumar Bhansali declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Raman Marwaha declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>25</day>
          <month>5</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24422.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Lorazepam is a benzodiazepine medication approved by the US Food and Drug Administration (FDA) for short-term relief of anxiety symptoms associated with anxiety disorders, anxiety-related insomnia, anesthesia premedication in adults to relieve anxiety or induce sedation or amnesia, and treatment of status epilepticus. Lorazepam is favored in inpatient settings for its rapid onset of action (1-3 minutes intravenously).&#x000a0;Off-label uses for lorazepam include rapid tranquilization of agitated patients, alcohol withdrawal delirium and syndrome, insomnia, panic disorder, delirium, chemotherapy-associated anticipatory nausea and vomiting (adjunct or breakthrough), vertigo, and psychogenic catatonia.&#x000a0;Lorazepam is used in various clinical practices and is often compared with other benzodiazepines. Clinicians from several specialties and at different levels of practice utilize it in acute, short-term, and long-term settings.&#x000a0;</p>
        <p>This activity reviews lorazepam, including its mechanism of action, adverse event profiles, and monitoring, and identifies potential drug-drug interactions through its pharmacokinetics.&#x000a0;This activity allows participating clinicians to make decisions and optimize dosage regimens while minimizing the adverse reactions of the drug. In addition, the&#x000a0;interprofessional healthcare team, comprising clinicians, pharmacists, and therapists, works together to provide appropriate treatment for patients with psychiatric conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate indications for lorazepam use based on patient presentation and clinical guidelines.</p></list-item><list-item><p>Implement appropriate monitoring protocols to assess patient response and potential adverse reactions to lorazepam therapy.</p></list-item><list-item><p>Select alternative treatment options or adjust lorazepam dosage based on individual patient characteristics and treatment goals.</p></list-item><list-item><p>Collaborate with interprofessional healthcare teams, including pharmacists and therapists, to ensure comprehensive patient care and treatment planning.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24422&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24422">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24422.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Lorazepam is a benzodiazepine medication approved by the US Food and Drug Administration (FDA) for various conditions. The drug is used in various clinical practices and is often compared with other benzodiazepines.&#x000a0;Lorazepam was developed by DJ Richards and was initially marketed in the United States in 1977.&#x000a0;Lorazepam is favored in inpatient settings as the sedative and anxiolytic drug of choice for its rapid onset of action (1-3 minutes) when administered intravenously (IV).<xref ref-type="bibr" rid="article-24422.r1">[1]</xref>&#x000a0; See <bold>Figure.&#x000a0;</bold>Lorazepam Organic Chemical Structure.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Short-term (4 months)&#x000a0;relief of anxiety symptoms&#x000a0;associated with anxiety disorders</p>
          </list-item>
          <list-item>
            <p>Anxiety-related insomnia</p>
          </list-item>
          <list-item>
            <p>Anesthesia premedication in adults to relieve anxiety or to induce sedation or amnesia</p>
          </list-item>
          <list-item>
            <p>Treatment of status epilepticus&#x000a0;<xref ref-type="bibr" rid="article-24422.r2">[2]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Rapid tranquilization of the agitated patient</p>
          </list-item>
          <list-item>
            <p>Alcohol withdrawal delirium and&#x000a0;syndrome</p>
          </list-item>
          <list-item>
            <p>Insomnia</p>
          </list-item>
          <list-item>
            <p>Panic disorder</p>
          </list-item>
          <list-item>
            <p>Delirium</p>
          </list-item>
          <list-item>
            <p>Chemotherapy-associated anticipatory nausea and vomiting (adjunct or breakthrough)</p>
          </list-item>
          <list-item>
            <p>Psychogenic catatonia</p>
          </list-item>
          <list-item>
            <p>Vertigo&#x000a0;<xref ref-type="bibr" rid="article-24422.r3">[3]</xref><xref ref-type="bibr" rid="article-24422.r4">[4]</xref><xref ref-type="bibr" rid="article-24422.r5">[5]</xref><xref ref-type="bibr" rid="article-24422.r6">[6]</xref><xref ref-type="bibr" rid="article-24422.r7">[7]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24422.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Lorazepam binds to benzodiazepine receptors on postsynaptic &#x003b3;-aminobutyric acid (GABA)-A ligand-gated chloride channel neurons at multiple sites within the central nervous system (CNS). This medication enhances the inhibitory effects of GABA, which increases the conductance of chloride ions in the cell. Consequently, a shift in chloride ions leads to hyperpolarization and stabilization of the cellular plasma membrane.<xref ref-type="bibr" rid="article-24422.r8">[8]</xref>&#x000a0;The inhibitory action in the amygdala is beneficial in anxiety disorders, while&#x000a0;the inhibitory activity in the cerebral cortex is beneficial in seizure disorders.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Lorazepam is well absorbed after oral administration. Peak concentrations are attained&#x000a0;2 hours following oral administration. The bioavailability of lorazepam is approximately 90%. Moreover, lorazepam freely crosses the blood-brain barrier via passive diffusion.</p>
        <p><bold>Distribution:</bold>&#x000a0;Lorazepam has a volume of distribution of 1.3 L/kg, and it binds to approximately 90% of plasma proteins. The drug crosses the blood-brain barrier via passive diffusion.</p>
        <p><bold>Metabolism:</bold>&#x000a0;Lorazepam undergoes conjugation in the liver and experiences enterohepatic recirculation. Lorazepam glucuronide is an inactive metabolite.&#x000a0;The medication undergoes direct glucuronidation without prior cytochrome p450 metabolism. Consequently,&#x000a0;lorazepam can be safely administered to patients with hepatic dysfunction with minimal impact on its pharmacokinetics.</p>
        <p><bold>Excretion:</bold>&#x000a0;Lorazepam has an elimination half-life of 14&#x000b1;5 hours and a clearance of 1.1&#x000b1;0.4 mL/min/kg. The drug is primarily excreted in the urine.<xref ref-type="bibr" rid="article-24422.r9">[9]</xref><xref ref-type="bibr" rid="article-24422.r10">[10]</xref></p>
      </sec>
      <sec id="article-24422.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths </bold>
</p>
        <p>Lorazepam is available in various formulations, including&#x000a0;oral tablets, oral concentrate solutions, extended-release capsules, and solutions.</p>
        <p>Lorazepam can be administered orally in strengths of&#x000a0;0.5 mg, 1 mg, and 2 mg tablets, as well as an oral concentrate solution of 2 mg/mL.&#x000a0;Extended-release capsules are also available in strengths of 1 mg, 2 mg, and 3 mg.&#x000a0;Additionally, lorazepam can be administered intravenously (IV) or via intramuscular (IM) injection, with solutions available in concentrations of 2 mg/mL and 4 mg/mL. The onset of action is typically 1 to 3 minutes when administered IV and 15 to 30 minutes when administered IM.</p>
        <p>
<bold>Adult Dosages</bold>
</p>
        <p><bold>Anxiety disorder:&#x000a0;</bold>The initial starting dosage of lorazepam&#x000a0;is 2 to 3 mg orally, which may be repeated 2 to 3 times daily. The recommended daily dosage should not exceed 10 mg.<xref ref-type="bibr" rid="article-24422.r11">[11]</xref></p>
        <p><bold>Insomnia due to anxiety or stress:&#x000a0;</bold>The recommended dosage for lorazepam is 0.5 to 2 mg orally at bedtime for patients aged 65 or younger and 0.5 to 1 mg for patients aged 65 or older.</p>
        <p><bold>Premedication for anesthesia:&#x000a0;</bold>When administered IM, the recommended dosage of lorazepam is 0.05 mg/kg administered 2 hours before surgery, with a maximum dose of 4 mg. If administered IV, the recommended dosage is 0.044 mg/kg administered 15 to 20 minutes before surgery, with a maximum dose of 4 mg. However, in patients aged 50 or older, the maximum dose should not exceed 2 mg.<xref ref-type="bibr" rid="article-24422.r12">[12]</xref></p>
        <p><bold>Status epilepticus:&#x000a0;</bold>When administered IV, lorazepam is typically given at a dose of 0.1 mg/kg, up to a maximum dose of 4 mg, and at a maximum infusion rate of 2 mg/min. This dose may be repeated every 5 to 10 minutes as needed. The dose must be&#x000a0;diluted with an equal volume of saline (1:1 dilution). According to the American Epilepsy Society guidelines, parenteral lorazepam is considered one of the first-line treatments for convulsive status epilepticus.<xref ref-type="bibr" rid="article-24422.r13">[13]</xref></p>
        <p><bold>Agitation in the intensive care unit patient:&#x000a0;</bold>The IV loading dose for lorazepam is 0.02 to 0.04 mg/kg, with a maximum single dose of 2 mg. The maintenance dosage of lorazepam&#x000a0;ranges from 0.02 to 0.06 mg/kg every 2 to 6 hours as needed, or a continuous infusion of 0.01 to 0.1 mg/kg/h, with a maximum dosing limit of less than 10 mg/h.</p>
        <p><bold>Alcohol withdrawal delirium:&#x000a0;</bold>The IV dosage of lorazepam is 1 to 4 mg every 5 to 15 minutes until the patient is calm, with the option to repeat the dose every hour as needed. For IM administration, the lorazepam&#x000a0;dosage is 1 to 4 mg every 30 to 60 minutes until the patient is calm, also with the option to repeat the dose every hour as needed.<xref ref-type="bibr" rid="article-24422.r14">[14]</xref></p>
        <p><bold>Alcohol withdrawal syndrome:&#x000a0;</bold>According to the American Society of Addiction Medicine clinical practice guidelines, lorazepam is one of the most frequently used drugs for&#x000a0;managing alcohol withdrawal. The symptom-triggered regimen can be administered orally, IM, or IV at 2 to 4 mg/h as needed, with the dose determined by a severity assessment scale. The fixed-dose regimen can be administered orally, IM, or IV at 2 mg every 6 hours for 4 doses, followed by 1 mg every 6 hours for 8 additional doses. Notably, a symptom-triggered regimen is preferred over fixed-dose regimens, requiring lower doses and shorter treatment durations. Lorazepam is preferred in patients with cirrhosis.<xref ref-type="bibr" rid="article-24422.r15">[15]</xref><xref ref-type="bibr" rid="article-24422.r16">[16]</xref></p>
        <p><bold>Chemotherapy-associated nausea and vomiting:&#x000a0;</bold>Lorazepam is used for breakthrough nausea or vomiting or as an adjunct to standard antiemetics.&#x000a0;The medication can be administered orally, IV, or sublingually at a dosage of 0.5 to 2 mg every 6 hours.</p>
        <p><bold>Psychogenic catatonia:&#x000a0;</bold>The IM dosage of lorazepam&#x000a0;is 1 to 2 mg, which can be repeated after 3 hours if the initial dose is ineffective and again after another 3 hours if needed. Lorazepam can be administered orally, IM, or IV, starting with an initial dose of 1 mg, which may be repeated after 5 minutes if necessary. If the initial challenge is unsuccessful, the dosage may be increased to 4 to 8 mg daily, with treatment continuing for up to 5 days.<xref ref-type="bibr" rid="article-24422.r17">[17]</xref></p>
        <p><bold>Vertigo:&#x000a0;</bold>According to the American Academy of Otolaryngology-Head and Neck Surgery, lorazepam is preferred at a dosage of 1 to 2 mg every 8 hours when a rapid onset of action&#x000a0;is required to relieve vertigo in Meniere disease.&#x000a0;However, the use of&#x000a0;benzodiazepines is not recommended for relieving vertigo in benign paroxysmal positional vertigo.<xref ref-type="bibr" rid="article-24422.r18">[18]</xref><xref ref-type="bibr" rid="article-24422.r19">[19]</xref></p>
        <p><bold>Severe agitation:&#x000a0;</bold>The American College of Emergency Physicians (ACEP) advises&#x000a0;using a combination of droperidol and midazolam or an atypical antipsychotic with midazolam for the rapid treatment of severe agitation in out-of-hospital or emergency department patients. If only one agent is used, ACEP recommends droperidol or an atypical antipsychotic. Haloperidol, alone or with lorazepam, is also recommended for effective treatment.<xref ref-type="bibr" rid="article-24422.r4">[4]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;The product labeling does not provide specific information on the use of lorazepam in patients with hepatic impairment. However, as discussed, lorazepam can be used cautiously in these patients. Alcohol-associated liver disease requires comprehensive treatment addressing both liver damage and the underlying alcohol use disorder (AUD). Alcohol withdrawal syndrome complicates AUD recovery and inpatient care for liver issues. In advanced liver disease, it is recommended to select benzodiazepines with reduced hepatic metabolism, such as lorazepam.<xref ref-type="bibr" rid="article-24422.r5">[5]</xref><xref ref-type="bibr" rid="article-24422.r9">[9]</xref></p>
        <p><bold>Renal impairment:</bold>&#x000a0;Manufacturers recommend taking precautions when using lorazepam in patients with renal disease, such as administering frequent doses over relatively short periods. According to a review, if benzodiazepines are required, lorazepam is a reasonable first-line choice for patients with end-stage renal disease.<xref ref-type="bibr" rid="article-24422.r20">[20]</xref></p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;Lorazepam is classified as a pregnancy category D medicine. Documented case reports and case-control studies suggest an increased risk of cleft palate and cleft lip when using lorazepam and other benzodiazepines during the first trimester. Third-trimester use of lorazepam and benzodiazepines is associated with an increased risk of causing neonatal withdrawal symptoms. If lorazepam needs to be used during pregnancy, it is recommended with extreme caution, and the benefits must outweigh the risks.<xref ref-type="bibr" rid="article-24422.r21">[21]</xref></p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;Lorazepam is detected in breast milk at low levels. Studies indicate that lorazepam does not cause adverse reactions in breastfed babies when mothers are taking standard dosages. Additionally, a safety scoring system evaluating psychotropic drugs used in lactating women suggests that lorazepam is safer than other benzodiazepines during breastfeeding.<xref ref-type="bibr" rid="article-24422.r22">[22]</xref><xref ref-type="bibr" rid="article-24422.r23">[23]</xref></p>
        <p><bold>Potentially inappropriate medication in older adults: </bold>According to the American Geriatric Society Beers Criteria, lorazepam is classified as a potentially inappropriate medication for older adults. The older population typically exhibits heightened sensitivity to benzodiazepines and reduced clearance rates. Consequently, they face an elevated risk of cognitive impairment, falls, and fractures when using lorazepam. However, its use may be considered reasonable for conditions such as seizure disorders, alcohol withdrawal, severe generalized anxiety disorder, and periprocedural sedation. When prescribed, it is advised to use the lowest effective dose.<xref ref-type="bibr" rid="article-24422.r24">[24]</xref><xref ref-type="bibr" rid="article-24422.r25">[25]</xref></p>
        <p><bold>Pediatric considerations:</bold> According to the American Epilepsy Society guidelines, IV lorazepam and IV diazepam are deemed effective in halting seizures in children (level A), whereas rectal diazepam (IM or intranasal) or buccal midazolam is considered probably effective (level B).<xref ref-type="bibr" rid="article-24422.r13">[13]</xref></p>
      </sec>
      <sec id="article-24422.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Similar to most benzodiazepines, lorazepam can induce adverse reactions such as CNS and respiratory depression, which are dose-dependent. Additional adverse effects of the drug are observed with higher doses.<xref ref-type="bibr" rid="article-24422.r21">[21]</xref><xref ref-type="bibr" rid="article-24422.r26">[26]</xref></p>
        <p>Severe adverse effects of lorazepam include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Respiratory depression and&#x000a0;failure</p>
          </list-item>
          <list-item>
            <p>Seizures</p>
          </list-item>
          <list-item>
            <p>Suicidality</p>
          </list-item>
          <list-item>
            <p>Dependency and abuse</p>
          </list-item>
          <list-item>
            <p>Tachycardia</p>
          </list-item>
          <list-item>
            <p>Hypotension</p>
          </list-item>
          <list-item>
            <p>Syncope</p>
          </list-item>
          <list-item>
            <p>Blood dyscrasias</p>
          </list-item>
          <list-item>
            <p>Jaundice</p>
          </list-item>
          <list-item>
            <p>Paradoxical reaction (hyperactive and aggressive behavior)</p>
          </list-item>
          <list-item>
            <p>Gangrene (intra-arterial)</p>
          </list-item>
          <list-item>
            <p>Withdrawal symptoms if abruptly discontinued after long-term use.</p>
          </list-item>
          <list-item>
            <p>Cognitive deficits</p>
          </list-item>
          <list-item>
            <p>Behavioral changes</p>
          </list-item>
          <list-item>
            <p>Paradoxical agitation</p>
          </list-item>
          <list-item>
            <p>Propylene glycol toxicity when using the parenteral formulation in high doses (hyponatremia and metabolic acidosis)&#x000a0;<xref ref-type="bibr" rid="article-24422.r15">[15]</xref><xref ref-type="bibr" rid="article-24422.r27">[27]</xref></p>
          </list-item>
        </list>
        <p>Common adverse effects of lorazepam include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Sedation</p>
          </list-item>
          <list-item>
            <p>Dizziness</p>
          </list-item>
          <list-item>
            <p>Asthenia</p>
          </list-item>
          <list-item>
            <p>Ataxia</p>
          </list-item>
          <list-item>
            <p>Local injection site reaction</p>
          </list-item>
          <list-item>
            <p>Respiratory depression</p>
          </list-item>
          <list-item>
            <p>Hypoventilation with IV use</p>
          </list-item>
          <list-item>
            <p>Hypotension</p>
          </list-item>
          <list-item>
            <p>Fatigue</p>
          </list-item>
          <list-item>
            <p>Amnesia</p>
          </list-item>
          <list-item>
            <p>Confusion</p>
          </list-item>
          <list-item>
            <p>Disinhibition</p>
          </list-item>
          <list-item>
            <p>Irritability</p>
          </list-item>
          <list-item>
            <p>Libido changes</p>
          </list-item>
          <list-item>
            <p>Menstrual irregularities</p>
          </list-item>
          <list-item>
            <p>Diplopia</p>
          </list-item>
          <list-item>
            <p>Dysarthria</p>
          </list-item>
          <list-item>
            <p>Appetite changes</p>
          </list-item>
          <list-item>
            <p>Constipation</p>
          </list-item>
          <list-item>
            <p>Incontinence</p>
          </list-item>
          <list-item>
            <p>Urinary retention</p>
          </list-item>
          <list-item>
            <p>Dystonia</p>
          </list-item>
          <list-item>
            <p>Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)&#x000a0;elevation</p>
          </list-item>
          <list-item>
            <p>In rare instances, lorazepam can cause acute liver injury (cholestatic pattern)&#x000a0;<xref ref-type="bibr" rid="article-24422.r28">[28]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Lorazepam interacts with other drugs, leading to CNS depression. Concurrent use of sedatives, hypnotics, opioids, cough and cold medicines, antiepileptics, muscle relaxers, and alcohol can worsen adverse reactions caused by lorazepam. When initiating treatment with UDP-glucuronosyltransferase (UGT) inhibitors, it is advisable to gradually taper off lorazepam to discontinue its use.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Metronidazole should not be co-administered with propylene glycol products found in parenteral lorazepam formulations, as it may precipitate a disulfiram-like reaction.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Kratom, a plant with partial opioid agonist effects, is widely misused in the United States. The concurrent use of kratom and benzodiazepines can significantly elevate the risk of severe CNS depression; therefore, it is crucial to avoid combining these drugs.<xref ref-type="bibr" rid="article-24422.r21">[21]</xref><xref ref-type="bibr" rid="article-24422.r29">[29]</xref><xref ref-type="bibr" rid="article-24422.r30">[30]</xref><xref ref-type="bibr" rid="article-24422.r31">[31]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24422.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p>Lorazepam is contraindicated in patients with a history of anaphylactic reactions to lorazepam, any component of the formulation, or other benzodiazepines (cross-sensitivity with other benzodiazepines may occur). The use of the drug is also contraindicated in neonates or premature infants, as well as in patients with severe respiratory impairment (except during mechanical ventilation), acute narrow-angle glaucoma, sleep apnea, severe respiratory insufficiency, and when administered intra-arterially.<xref ref-type="bibr" rid="article-24422.r32">[32]</xref>&#x000a0;</p>
        <p>Lorazepam and other benzodiazepines are not recommended as first-line agents for anxiety and other psychiatric disorder symptoms during the first and third trimesters of pregnancy. Lorazepam and other benzodiazepines carry an elevated risk of abuse, misuse, and dependence. Consequently, they are contraindicated in patients who are actively using illicit substances and drugs. With the exception of patients undergoing detoxification for AUD, lorazepam and other benzodiazepines should not be used in individuals with a history of alcohol dependence or abuse who are not in remission. Combined use of alcohol and lorazepam in overdose poses an increased risk of fatality, including death.<xref ref-type="bibr" rid="article-24422.r21">[21]</xref></p>
        <p>The injection formulation of lorazepam contains polyethylene glycol, propylene glycol, or benzyl alcohol, making hypersensitivity to these excipients a contraindication for use.<xref ref-type="bibr" rid="article-24422.r33">[33]</xref>&#x000a0;As extended-release capsules contain tartrazine, patients with a history of allergic reactions should avoid using the capsules.</p>
        <p>
<bold>Box Warning</bold>
</p>
        <p>The concurrent use of benzodiazepines with opioids can result in sedation, severe respiratory depression, coma, and death. Therefore, it is crucial to avoid the combination of these medications.<xref ref-type="bibr" rid="article-24422.r34">[34]</xref></p>
      </sec>
      <sec id="article-24422.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Respiratory and cardiovascular status, blood pressure, and heart rate should be regularly monitored in patients administered lorazepam. Clinicians should monitor the patient's complete blood count, liver function tests, and lactate dehydrogenase levels for long-term therapy. In cases of high-dose or continuous IV use or patients with renal impairment, clinical signs of propylene glycol toxicity, serum creatinine, blood urea nitrogen, serum lactate, and osmolality gap should be monitored.<xref ref-type="bibr" rid="article-24422.r35">[35]</xref> The depth of sedation should be closely monitored in critically ill patients.</p>
        <p>Lorazepam is classified as a schedule IV drug, and patients may develop dependence and tolerance with prolonged use. Thus, utilizing&#x000a0;the lowest effective dose of lorazepam&#x000a0;for the shortest duration is advised. When discontinuing lorazepam, a tapering schedule of 0.5 mg every 3 days is recommended to mitigate withdrawal symptoms.<xref ref-type="bibr" rid="article-24422.r36">[36]</xref>&#x000a0;The dose of lorazepam should be monitored and adjusted according to the Clinical Institute Withdrawal Assessment for Alcohol&#x02013;Revised (CIWA-Ar) protocol.<xref ref-type="bibr" rid="article-24422.r37">[37]</xref>&#x000a0;Improvement in anxiety should be monitored using a validated scoring system such as the Hamilton Anxiety Scale.<xref ref-type="bibr" rid="article-24422.r38">[38]</xref></p>
      </sec>
      <sec id="article-24422.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Lorazepam can cause CNS and respiratory&#x000a0;depression in overdose, potentially leading to hypotension, ataxia, confusion, coma, extreme drowsiness, muscle weakness, and death.<xref ref-type="bibr" rid="article-24422.r21">[21]</xref> Concurrent use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death.<xref ref-type="bibr" rid="article-24422.r39">[39]</xref> Therefore, the prescribing of benzodiazepines and opioids together should be reserved for patients with inadequate alternative treatment options. The dosage and duration of lorazepam must be limited based on the indication, and patients require surveillance for signs and symptoms of respiratory depression. While lorazepam, similar to other benzodiazepines, is rarely associated with elevated serum ALT, clinically apparent liver injury from lorazepam is infrequent.<xref ref-type="bibr" rid="article-24422.r40">[40]</xref>&#x000a0;The clinical pattern of acute liver injury from benzodiazepines is typically cholestatic.&#x000a0;</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>Flumazenil&#x000a0;is an antidote for benzodiazepine toxicity.<xref ref-type="bibr" rid="article-24422.r41">[41]</xref> Flumazenil competes with benzodiazepines for binding at the GABA/benzodiazepine&#x000a0;receptor complex. However, abrupt awakening following administration can lead to dysphoria, agitation, and increased adverse effects.<xref ref-type="bibr" rid="article-24422.r42">[42]</xref> In patients undergoing chronic benzodiazepine therapy, the sudden interruption of benzodiazepine antagonism by flumazenil may induce benzodiazepine withdrawal, including seizures.&#x000a0;Notably, flumazenil has minimal effects on benzodiazepine-induced respiratory depression, and appropriate ventilatory support should be available when treating acute benzodiazepine overdose.<xref ref-type="bibr" rid="article-24422.r43">[43]</xref>&#x000a0;A recent case report detailed a severe lorazepam overdose with absent corneal, oculocephalic, and oculovestibular reflexes; however, the patient recovered after receiving 0.25 mg IV flumazenil.<xref ref-type="bibr" rid="article-24422.r44">[44]</xref></p>
      </sec>
      <sec id="article-24422.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Similar to other benzodiazepine medications,&#x000a0;lorazepam can be highly addictive. Therefore, a collaborative approach involving an interprofessional healthcare team is essential for prescribing and managing these medications. This team typically includes clinicians (MDs, DOs, NPs, and PAs), psychiatrists, nursing staff, and pharmacists, all of whom should remain vigilant for signs of misuse or adverse effects. By adopting this approach, the team can prevent misuse and unintended adverse events, ultimately optimizing therapy.</p>
        <p>High doses or prolonged durations of lorazepam require careful consideration, especially in patients with a history of substance use disorder or concurrent opioid prescriptions. Managing such cases necessitates an interprofessional healthcare team involving nurses, pharmacists, and various specialist clinicians. This team should diligently monitor for signs of abuse, diversion, or concurrent use with other prescription or non-prescription sedative medications. Prescribers and pharmacists must closely monitor treatment, offer patient education, and exercise vigilance when prescribing benzodiazepines such as lorazepam. Additionally, the prescription drug monitoring program can help identify potential misuse of lorazepam.<xref ref-type="bibr" rid="article-24422.r45">[45]</xref>&#x000a0;</p>
        <p>During a lorazepam shortage in 2022, interdisciplinary collaboration of healthcare teams led to alternative treatment recommendations, primarily involving the use of midazolam in palliative care. Benzodiazepine utilization notably decreased during the shortage but reverted to baseline levels after its resolution. Fortunately, no patient safety events occurred, and care experiences remained unaffected. This collaborative effort effectively conserved lorazepam for patients lacking alternatives while ensuring effective management of palliative care needs.<xref ref-type="bibr" rid="article-24422.r46">[46]</xref>&#x000a0;Moving forward, the interprofessional healthcare team should utilize state and federal controlled substance monitoring and diversion databases to identify high-risk patients with multiple and frequent prescriptions for benzodiazepines, opioids, muscle relaxants, and other sedative-hypnotics. Safe prescribing practices are achievable only through interprofessional treatment overseen by clinicians, pharmacists, and nurses.</p>
      </sec>
      <sec id="article-24422.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24422&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24422">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24422/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24422">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-24422.s11">
        <fig id="article-24422.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Lorazepam Organic Chemical Structure. Due&#x000a0;to the fast (1 to 3 minutes) onset of action when administered intravenously, lorazepam is commonly used as the sedative and anxiolytic of choice in diverse practice settings. National Center for Biotechnology Information. PubChem Compound Summary for CID 3958, Lorazepam. https://pubchem.ncbi.nlm.nih.gov/compound/Lorazepam. Accessed July 14, 2024.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="imagefly" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-24422.s12">
        <title>References</title>
        <ref id="article-24422.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hui</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Benzodiazepines for agitation in patients with delirium: selecting the right patient, right time, and right indication.</article-title>
            <source>Curr Opin Support Palliat Care</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>489</fpage>
            <page-range>489-494</page-range>
            <pub-id pub-id-type="pmid">30239384</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leppik</surname>
                <given-names>IE</given-names>
              </name>
            </person-group>
            <article-title>Status epilepticus in the elderly.</article-title>
            <source>Epilepsia</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>59 Suppl 2</volume>
            <fpage>140</fpage>
            <page-range>140-143</page-range>
            <pub-id pub-id-type="pmid">30159881</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Eyal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Marom</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Trends in utilization of benzodiazepine and Z-drugs in Israel.</article-title>
            <source>Pharmacoepidemiol Drug Saf</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>26</volume>
            <issue>12</issue>
            <fpage>1555</fpage>
            <page-range>1555-1560</page-range>
            <pub-id pub-id-type="pmid">29027336</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>American College of Emergency Physicians Clinical Policies Subcommittee (Writing Committee) on Severe Agitation</collab>
              <name>
                <surname>Thiessen</surname>
                <given-names>MEW</given-names>
              </name>
              <name>
                <surname>Godwin</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Hatten</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Whittle</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Haukoos</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Diercks</surname>
                <given-names>DB</given-names>
              </name>
              <collab>Members of the American College of Emergency Physicians Clinical Policies Committee (Oversight Committee)</collab>
              <name>
                <surname>Diercks</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Byyny</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Carpenter</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gemme</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Gerardo</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Godwin</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Hatten</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Haukoos</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Kaji</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kwok</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lo</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Mace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Moran</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Promes</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Shih</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Silvers</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Slivinski</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Thiessen</surname>
                <given-names>MEW</given-names>
              </name>
              <name>
                <surname>Tomaszewski</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Valente</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Wall</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Westafer</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cantrill</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Finnell</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Schulz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vandertulip</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Clinical Policy: Critical Issues in the Evaluation and Management of Adult Out-of-Hospital or Emergency Department Patients Presenting With Severe Agitation: Approved by the ACEP Board of Directors, October 6, 2023.</article-title>
            <source>Ann Emerg Med</source>
            <year>2024</year>
            <month>Jan</month>
            <volume>83</volume>
            <issue>1</issue>
            <fpage>e1</fpage>
            <page-range>e1-e30</page-range>
            <pub-id pub-id-type="pmid">38105109</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ratner</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Blaney</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rastegar</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Management of alcohol withdrawal syndrome in patients with alcohol-associated liver disease.</article-title>
            <source>Hepatol Commun</source>
            <year>2024</year>
            <month>Feb</month>
            <day>01</day>
            <volume>8</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">38251886</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elmarasi</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Abdelhady</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mahgoub</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Thought Blocking as a Manifestation of Catatonia: A Case Report.</article-title>
            <source>J Nerv Ment Dis</source>
            <year>2024</year>
            <month>Feb</month>
            <day>01</day>
            <volume>212</volume>
            <issue>2</issue>
            <fpage>120</fpage>
            <page-range>120-121</page-range>
            <pub-id pub-id-type="pmid">38290105</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Heidari</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Asadollahi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Habibi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shahrami</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mansouri</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kariman</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Intravenous promethazine versus lorazepam for the treatment of peripheral vertigo in the emergency department: A double blind, randomized clinical trial of efficacy and safety.</article-title>
            <source>J Vestib Res</source>
            <year>2014</year>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>39</fpage>
            <page-range>39-47</page-range>
            <pub-id pub-id-type="pmid">24594499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vinkers</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Tijdink</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Luykx</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Vis</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>[Choosing the correct benzodiazepine: mechanism of action and pharmacokinetics].</article-title>
            <source>Ned Tijdschr Geneeskd</source>
            <year>2012</year>
            <volume>155</volume>
            <issue>35</issue>
            <fpage>A4900</fpage>
            <pub-id pub-id-type="pmid">22929751</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Griffin</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Bueno</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Benzodiazepine pharmacology and central nervous system-mediated effects.</article-title>
            <source>Ochsner J</source>
            <year>2013</year>
            <season>Summer</season>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>214</fpage>
            <page-range>214-23</page-range>
            <pub-id pub-id-type="pmid">23789008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yeary</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Garavaglia</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McKnight</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Change in Management of Status Epilepticus With the Addition of Neurointensivist-Led Neurocritical Care Team at a Rural Academic Medical Center.</article-title>
            <source>Hosp Pharm</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>53</volume>
            <issue>5</issue>
            <fpage>303</fpage>
            <page-range>303-307</page-range>
            <pub-id pub-id-type="pmid">30210147</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vlastra</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Delewi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rohling</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Wagenaar</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Hirsch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Meesterman</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Vis</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Wykrzykowska</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Koch</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>de Winter</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Baan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Piek</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Sprangers</surname>
                <given-names>MAG</given-names>
              </name>
              <name>
                <surname>Henriques</surname>
                <given-names>JPS</given-names>
              </name>
            </person-group>
            <article-title>Premedication to reduce anxiety in patients undergoing coronary angiography and percutaneous coronary intervention.</article-title>
            <source>Open Heart</source>
            <year>2018</year>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>e000833</fpage>
            <pub-id pub-id-type="pmid">30275956</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maurice-Szamburski</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Auquier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Viarre-Oreal</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Cuvillon</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Carles</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ripart</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Honore</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Triglia</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Loundou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bruder</surname>
                <given-names>N</given-names>
              </name>
              <collab>PremedX Study Investigators</collab>
            </person-group>
            <article-title>Effect of sedative premedication on patient experience after general anesthesia: a randomized clinical trial.</article-title>
            <source>JAMA</source>
            <year>2015</year>
            <month>Mar</month>
            <day>03</day>
            <volume>313</volume>
            <issue>9</issue>
            <fpage>916</fpage>
            <page-range>916-25</page-range>
            <pub-id pub-id-type="pmid">25734733</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glauser</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shinnar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gloss</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Alldredge</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Arya</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bainbridge</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bare</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bleck</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dodson</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Garrity</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jagoda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lowenstein</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pellock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Riviello</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sloan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Treiman</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society.</article-title>
            <source>Epilepsy Curr</source>
            <year>2016</year>
            <season>Jan-Feb</season>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>48</fpage>
            <page-range>48-61</page-range>
            <pub-id pub-id-type="pmid">26900382</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heavner</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Akg&#x000fc;n</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Heavner</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Eng</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Drew</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pritchard</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Honiden</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Implementation of an ICU-Specific Alcohol Withdrawal Syndrome Management Protocol Reduces the Need for Mechanical Ventilation.</article-title>
            <source>Pharmacotherapy</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>38</volume>
            <issue>7</issue>
            <fpage>701</fpage>
            <page-range>701-713</page-range>
            <pub-id pub-id-type="pmid">29800507</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <article-title>The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management.</article-title>
            <source>J Addict Med</source>
            <year>2020</year>
            <season>May/Jun</season>
            <volume>14</volume>
            <issue>3S Suppl 1</issue>
            <fpage>1</fpage>
            <page-range>1-72</page-range>
            <pub-id pub-id-type="pmid">32511109</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gershkovich</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wasan</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Ribeyre</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ibrahim</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>McNeill</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Effect of variations in treatment regimen and liver cirrhosis on exposure to benzodiazepines during treatment of alcohol withdrawal syndrome.</article-title>
            <source>Drugs Context</source>
            <year>2015</year>
            <volume>4</volume>
            <fpage>212287</fpage>
            <pub-id pub-id-type="pmid">26322116</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cevher Binici</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Topal</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Demir Samurcu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cans&#x00131;z</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Savc&#x00131;</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>&#x000d6;zt&#x000fc;rk</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>&#x000d6;zyurt</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tufan</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Response of Catatonia to Amisulpride and Lorazepam in an Adolescent with Schizophenia.</article-title>
            <source>J Child Adolesc Psychopharmacol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>28</volume>
            <issue>2</issue>
            <fpage>151</fpage>
            <page-range>151-152</page-range>
            <pub-id pub-id-type="pmid">29406775</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Basura</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Monfared</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Antonelli</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Burkard</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bush</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Bykowski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Colandrea</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Derebery</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Kerber</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Koopman</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Kuch</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Marcolini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>McKinnon</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Ruckenstein</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Valenzuela</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Vosooney</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Nnacheta</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Dhepyasuwan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Buchanan</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Clinical Practice Guideline: M&#x000e9;ni&#x000e8;re's Disease.</article-title>
            <source>Otolaryngol Head Neck Surg</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>162</volume>
            <issue>2_suppl</issue>
            <fpage>S1</fpage>
            <page-range>S1-S55</page-range>
            <pub-id pub-id-type="pmid">32267799</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhattacharyya</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gubbels</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Edlow</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>El-Kashlan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fife</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Holmberg</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Mahoney</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hollingsworth</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Seidman</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Steiner</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Do</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Voelker</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Waguespack</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Corrigan</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Clinical Practice Guideline: Benign Paroxysmal Positional Vertigo (Update).</article-title>
            <source>Otolaryngol Head Neck Surg</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>156</volume>
            <issue>3_suppl</issue>
            <fpage>S1</fpage>
            <page-range>S1-S47</page-range>
            <pub-id pub-id-type="pmid">28248609</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilcock</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Charlesworth</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Twycross</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Waddington</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Worthington</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Murtagh</surname>
                <given-names>FEM</given-names>
              </name>
              <name>
                <surname>Beavis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mihalyo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kotlinska-Lemieszek</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Prescribing Non-Opioid Drugs in End-Stage Kidney Disease.</article-title>
            <source>J Pain Symptom Manage</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>54</volume>
            <issue>5</issue>
            <fpage>776</fpage>
            <page-range>776-787</page-range>
            <pub-id pub-id-type="pmid">28843456</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <article-title>Ativan (Lorazepam).</article-title>
            <source>J Addict Nurs</source>
            <year>2012</year>
            <month>May</month>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>141</fpage>
            <page-range>141-2</page-range>
            <pub-id pub-id-type="pmid">22548613</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r22">
          <label>22</label>
          <element-citation publication-type="book">
            <chapter-title>Lorazepam</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>1</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000290</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uguz</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>A New Safety Scoring System for the Use of Psychotropic Drugs During Lactation.</article-title>
            <source>Am J Ther</source>
            <string-date>2021 Jan-Feb 01</string-date>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>e118</fpage>
            <page-range>e118-e126</page-range>
            <pub-id pub-id-type="pmid">30601177</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <collab>By the 2019 American Geriatrics Society Beers Criteria&#x000ae; Update Expert Panel</collab>
            <article-title>American Geriatrics Society 2019 Updated AGS Beers Criteria&#x000ae; for Potentially Inappropriate Medication Use in Older Adults.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>67</volume>
            <issue>4</issue>
            <fpage>674</fpage>
            <page-range>674-694</page-range>
            <pub-id pub-id-type="pmid">30693946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hou</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Effects of tranquilization therapy in elderly patients suffering from chronic non-communicable diseases: A meta-analysis.</article-title>
            <source>Acta Pharm</source>
            <year>2023</year>
            <month>Mar</month>
            <day>01</day>
            <volume>73</volume>
            <issue>1</issue>
            <fpage>43</fpage>
            <page-range>43-57</page-range>
            <pub-id pub-id-type="pmid">36692463</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strand</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>M&#x000f8;rland</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sl&#x000f8;rdal</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Riedel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Innerdal</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Aamo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mathisrud</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vindenes</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Conversion factors for assessment of driving impairment after exposure to multiple benzodiazepines/z-hypnotics or opioids.</article-title>
            <source>Forensic Sci Int</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>281</volume>
            <fpage>29</fpage>
            <page-range>29-36</page-range>
            <pub-id pub-id-type="pmid">29101905</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonzalez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Upadhyaya</surname>
                <given-names>VD</given-names>
              </name>
              <name>
                <surname>Manna</surname>
                <given-names>ZT</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Christopher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Douedi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Paradoxical Excitation Following Intravenous Lorazepam Administration for Alcohol Withdrawal - A Case Presentation and Literature Review.</article-title>
            <source>J Pharm Pract</source>
            <year>2023</year>
            <month>Oct</month>
            <volume>36</volume>
            <issue>5</issue>
            <fpage>1244</fpage>
            <page-range>1244-1248</page-range>
            <pub-id pub-id-type="pmid">35466771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r28">
          <label>28</label>
          <element-citation publication-type="book">
            <chapter-title>Lorazepam</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>22</day>
            <pub-id pub-id-type="pmid">31643878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lim</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Poole</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Pageler</surname>
                <given-names>NM</given-names>
              </name>
            </person-group>
            <article-title>Propylene glycol toxicity in children.</article-title>
            <source>J Pediatr Pharmacol Ther</source>
            <year>2014</year>
            <season>Oct-Dec</season>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>277</fpage>
            <page-range>277-82</page-range>
            <pub-id pub-id-type="pmid">25762872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palamar</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Past-Year Kratom Use in the U.S.: Estimates From a Nationally Representative Sample.</article-title>
            <source>Am J Prev Med</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>61</volume>
            <issue>2</issue>
            <fpage>240</fpage>
            <page-range>240-245</page-range>
            <pub-id pub-id-type="pmid">34027890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Narayanan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grundmann</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Vicknasingam</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>The Use of Benzodiazepines among Kratom (<italic>Mitragyna Speciosa</italic> Korth.) Users.</article-title>
            <source>J Psychoactive Drugs</source>
            <year>2020</year>
            <season>Jan-Mar</season>
            <volume>52</volume>
            <issue>1</issue>
            <fpage>86</fpage>
            <page-range>86-92</page-range>
            <pub-id pub-id-type="pmid">31218929</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naso</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Optimizing patient safety by preventing combined use of intramuscular olanzapine and parenteral benzodiazepines.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2008</year>
            <month>Jun</month>
            <day>15</day>
            <volume>65</volume>
            <issue>12</issue>
            <fpage>1180</fpage>
            <page-range>1180-3</page-range>
            <pub-id pub-id-type="pmid">18541690</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilson</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Reardon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Theodore</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Farber</surname>
                <given-names>HW</given-names>
              </name>
            </person-group>
            <article-title>Propylene glycol toxicity: a severe iatrogenic illness in ICU patients receiving IV benzodiazepines: a case series and prospective, observational pilot study.</article-title>
            <source>Chest</source>
            <year>2005</year>
            <month>Sep</month>
            <volume>128</volume>
            <issue>3</issue>
            <fpage>1674</fpage>
            <page-range>1674-81</page-range>
            <pub-id pub-id-type="pmid">16162774</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aschenbrenner</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Stronger Boxed Warning for Benzodiazepines.</article-title>
            <source>Am J Nurs</source>
            <year>2021</year>
            <month>Mar</month>
            <day>01</day>
            <volume>121</volume>
            <issue>3</issue>
            <fpage>22</fpage>
            <page-range>22-23</page-range>
            <pub-id pub-id-type="pmid">33625005</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barnes</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Gerst</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Terrell</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Mullins</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Osmol gap as a surrogate marker for serum propylene glycol concentrations in patients receiving lorazepam for sedation.</article-title>
            <source>Pharmacotherapy</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>23</fpage>
            <page-range>23-33</page-range>
            <pub-id pub-id-type="pmid">16422667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Petrides</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Melanson</surname>
                <given-names>SEF</given-names>
              </name>
              <name>
                <surname>Kantartjis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Le</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Demetriou</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Flood</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Monitoring opioid and benzodiazepine use and abuse: Is oral fluid or urine the preferred specimen type?</article-title>
            <source>Clin Chim Acta</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>481</volume>
            <fpage>75</fpage>
            <page-range>75-82</page-range>
            <pub-id pub-id-type="pmid">29499200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reoux</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Routine hospital alcohol detoxification practice compared to symptom triggered management with an Objective Withdrawal Scale (CIWA-Ar).</article-title>
            <source>Am J Addict</source>
            <year>2000</year>
            <season>Spring</season>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>135</fpage>
            <page-range>135-44</page-range>
            <pub-id pub-id-type="pmid">10934575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zu</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Clinical efficacy and safety of low-dose doxepin in Chinese patients with generalized anxiety disorder: A before-after study.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2022</year>
            <month>Oct</month>
            <day>21</day>
            <volume>101</volume>
            <issue>42</issue>
            <fpage>e31201</fpage>
            <pub-id pub-id-type="pmid">36281170</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xiang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lei</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The fate and risk assessment of psychiatric pharmaceuticals from psychiatric hospital effluent.</article-title>
            <source>Ecotoxicol Environ Saf</source>
            <year>2018</year>
            <month>Apr</month>
            <day>15</day>
            <volume>150</volume>
            <fpage>289</fpage>
            <page-range>289-296</page-range>
            <pub-id pub-id-type="pmid">29289864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kogi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Honda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kawai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Okamoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fujioka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Murata</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Lorazepam as a Cause of Drug-Induced Liver Injury.</article-title>
            <source>Case Rep Gastroenterol</source>
            <year>2018</year>
            <season>May-Aug</season>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>546</fpage>
            <page-range>546-550</page-range>
            <pub-id pub-id-type="pmid">30283291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wallace</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Trimble</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Use of a flumazenil infusion to treat chlordiazepoxide toxicity.</article-title>
            <source>Acute Med</source>
            <year>2017</year>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <page-range>30-34</page-range>
            <pub-id pub-id-type="pmid">28424803</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Niedrig</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Hoppe</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>M&#x000e4;chler</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Russmann</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Russmann</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Benzodiazepine Use During Hospitalization: Automated Identification of Potential Medication Errors and Systematic Assessment of Preventable Adverse Events.</article-title>
            <source>PLoS One</source>
            <year>2016</year>
            <volume>11</volume>
            <issue>10</issue>
            <fpage>e0163224</fpage>
            <pub-id pub-id-type="pmid">27711224</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rubio Gonz&#x000e1;lez</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Redondo Mart&#x000ed;n</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ru&#x000ed;z L&#x000f3;pez Del Prado</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;oz Moreno</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Vel&#x000e1;zquez Miranda</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[Hospital Emergencies Associated with the Consumption of Hypnotics and Sedatives, 2009-2013,Castilla y Le&#x000f3;n, Spain].</article-title>
            <source>Rev Esp Salud Publica</source>
            <year>2016</year>
            <month>Oct</month>
            <day>24</day>
            <volume>90</volume>
            <fpage>e1</fpage>
            <page-range>e1-e12</page-range>
            <pub-id pub-id-type="pmid">27775683</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thumtecho</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wainipitapong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chunamchai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Suteparuk</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Alprazolam and lorazepam overdose and the absence of brainstem reflexes.</article-title>
            <source>BMJ Case Rep</source>
            <year>2022</year>
            <month>May</month>
            <day>10</day>
            <volume>15</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">35537772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Mandatory use of prescription drug monitoring program and benzodiazepine prescribing among U.S. Medicaid enrollees.</article-title>
            <source>Subst Abus</source>
            <year>2021</year>
            <volume>42</volume>
            <issue>3</issue>
            <fpage>294</fpage>
            <page-range>294-301</page-range>
            <pub-id pub-id-type="pmid">31697195</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24422.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hartung</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fatima</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Noreika</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Cassel</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>KS</given-names>
              </name>
            </person-group>
            <article-title>Using Interdisciplinary Teams to Mitigate the Effects of Drug Shortages in Palliative Care: The Case of Lorazepam Injection.</article-title>
            <source>J Pain Palliat Care Pharmacother</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>336</fpage>
            <page-range>336-341</page-range>
            <pub-id pub-id-type="pmid">37870502</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
